Covid-19: Oxford vaccine offers less South African variant protection
Oxford-AstraZeneca’s vaccine offers “minimal protection” against mild disease from the South Africa variant, scientists say early trials suggest. A new study, not yet peer reviewed, involved about 2,000 people who were on average 31 years old. But Prof Sarah Gilbert, Oxford lead vaccine developer, said vaccines should still protect against severe disease. She said developers were likely to have a…
Read More